Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
Tirzepatide is a prescription injectable medication that combines GLP-1 and GIP receptor agonism to improve blood glucose control and support weight reduction in adults with type 2 diabetes. Administered once weekly, it enhances insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite. Clinical trials have shown significant reductions in HbA1c and body weight compared with placebo and some other glucose-lowering therapies. Common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and patients should be monitored for potential pancreatitis, gallbladder disease, and thyroid C-cell tumors. Tirzepatide is not indicated for type 1 diabetes or diabetic ketoacidosis. Treatment should be individualized, and decisions should follow a discussion of benefits and risks with a healthcare provider.
Available for research purposes only
Tirzepatide is a prescription injectable medication that combines GLP-1 and GIP receptor agonism to improve blood glucose control and support weight reduction in adults with type 2 diabetes. Administered once weekly, it enhances insulin secretion in a glucose-dependent manner, suppresses inappropriate glucagon release, slows gastric emptying, and reduces appetite. Clinical trials have shown significant reductions in HbA1c and body weight compared with placebo and some other glucose-lowering therapies. Common side effects are gastrointestinal — nausea, vomiting, diarrhea, and constipation — and patients should be monitored for potential pancreatitis, gallbladder disease, and thyroid C-cell tumors. Tirzepatide is not indicated for type 1 diabetes or diabetic ketoacidosis. Treatment should be individualized, and decisions should follow a discussion of benefits and risks with a healthcare provider.
Available for research purposes only